SCHEMBL19730107

SCHEMBL19730107

CNc1nccc2c1c(CCC(=O)OC)nn2Cc1ccc(OC)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.45
CYP11B2 P19099 2/20 0.45
JAK2 O60674 1/20 0.40
PTGER4 P35408 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
CCR4 P51679 1/20 0.37
P2RX3 P56373 1/20 0.36
CSF1R P07333 2/20 0.36
POLB P06746 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
F2RL1 P55085 1/20 0.36
DYRK1A Q13627 1/20 0.36
BUB1 O43683 2/20 0.35
NR3C2 P08235 1/20 0.35
ALOX15 P16050 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 1/20 0.35
ALPL P05186 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31500890 1.00 CYP11B1 (0.45) CYP11B1CYP11B2JAK2PTGER4CNR1
SCHEMBL19730012 0.92 LMNA (0.43) CYP11B1CYP11B2JAK2PTGER4CNR1
SCHEMBL415781 0.88 CYP11B1 (0.47) CYP11B1CYP11B2JAK2PTGER4CNR1
SCHEMBL3777337 0.85 JAK2 (0.49) CYP11B1CYP11B2JAK2P2RX3POLB
SCHEMBL883468 0.85 JAK2 (0.48) CYP11B1CYP11B2JAK2
SCHEMBL19730053 0.79 CNR1 (0.43) JAK2PTGER4CNR1CNR2CCR4
SCHEMBL444498 0.78 LMNA (0.45) PTGER4CNR1CNR2LMNA
SCHEMBL3781866 0.78 JAK2 (0.49) JAK2POLBRXFP1LMNA
SCHEMBL19730136 0.77 JAK2 (0.39) JAK2PTGER4CNR1CNR2CCR4
SCHEMBL21434366 0.77 JAK2 (0.39) JAK2PTGER4CNR1CNR2CCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10918645-B2 Substituted tricyclic heterocyclic compounds and use thereof LIFEARC (GB) 2021-02-16 US disclosed
US-20190307763-A1 SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AND USE THEREOF LIFEARC (GB) 2019-10-10 US disclosed
WO-2017215600-A1 SUBSTITUTED TRICYCLIC HERTEOCYCLIC COMPOUNDS AND USE THEREOF SUZHOU YABAO PHARMACEUTICAL R&D CO., LTD. (CN) 2017-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10918645-B2 Substituted tricyclic heterocyclic compounds and use thereof MAPT, TTBK1, TNK2 CYP11B1 81/4885CYP11B2 105/4885JAK2 1723/4885
US-20190307763-A1 SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AND USE THEREOF MAPT, NNMT, TKFC CYP11B1 17/4885CYP11B2 35/4885JAK2 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.